Last reviewed · How we verify
NCT06978218
Brain Fog and Life Quality in Menopause
trial in Menopause in 122 participants. Completed in 16 July 2025.
16 July 2025
Quick facts
| Lead sponsor | Merve Coskun |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 122 |
| Start date | 8 May 2025 |
| Primary completion | 16 July 2025 |
| Estimated completion | 16 July 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Menopause — all drugs for Menopause →
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
- Memory Disorders — all drugs for Memory Disorders →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Merve Coskun
Who can join
Adults 40 to 60, female only, with Menopause or Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study aims to investigate cognitive changes in women undergoing the menopausal transition, with a specific focus on the prevalence, characteristics, and impact of brain fog. The research will assess how declining estrogen levels influence cognitive domains such as memory, attention, and executive function across different menopausal stages (perimenopause, menopause, and postmenopause). Through a comparative and observational design, the study will evaluate the relationship between subjective cognitive complaints and menopause-specific quality of life. Findings are expected to inform the development of non-pharmacological strategies-such as lifestyle modifications and cognitive health interventions-to mitigate cognitive decline and improve overall well-being in midlife women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06978218
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Menopause
Currently open trials in the same condition.
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
- NCT07135232 — The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. · NA · recruiting
- NCT06975111 — Focusing on the Menopausal Transition to Improve Mid-Life Women's Health · Phase 2, PHASE3 · recruiting
- NCT07393672 — Effects of Hemp-Derived Cannabinoids on Menopause Symptoms · Phase 2 · recruiting
- NCT07412093 — The Effect of Progressive Relaxation Exercises and Planned Education on Menopausal Symptoms, Perceived Stress, and Anxie · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06978218 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Merve Coskun
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978218.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing